Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies

Executive Summary

Roivant will use the cash to fund other "Vants" that develop drugs or make the process more efficient. Also, Zealand launches its IPO, Apellis raises a $60m Series E and BioMarin tops recent offerings.

Advertisement

Related Content

Celgene Revamps IO Deal With Emerging Biotech Sutro; Takeover Option Removed
Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones
Pipeline Watch: Phase II Readouts With SPK-8011, Velusetrag, GBR-830
Tymlos Inclusion Stands Out As Express Scripts Reveals 2018 Formulary
Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace
Roivant's Ramaswamy Woos Celgene's Fouse To Lead Dermavant
Celgene Eyes IO Growth With BeiGene China Pact
Full Circle: David Hung Looks Forward To Axovant's Alzheimer's Data, Reflects On Medivation
Pipeline Watch: Phase III Trials In Prostate Cancer, Diffuse Large B-cell Lymphoma
Year's First 4 IPOs Go South As Proteostasis, AveXis Launch

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel